|
|
|
|
Optelec Spearheads Low Vision Trend towards High Contrast with Low Magnification
BARENDRECHT, Netherlands--(BUSINESS WIRE)--Optelec, world leader in innovative and life-changing assistive technologies for the visually impaired and blind, announces the new 1X magnification functionality in the flagship Optelec ClearView+ High Definition (HD)...
|
|
|
Lucentis drove Roche sales in 2009
This web site just attempted to open a window, but it was blocked by your pop-up blocker.To see pop-up windows in the O.N.E. Network, you need to add this site to your allowed sites list. Two commonly-used popup blockers are: Google Toolbar Internet...
|
|
|
Financing Deal to Fund Phase 2 Trial of Wet AMD Therapy
Ophthotech Corp.(Princeton, NJ) announced that it has closed a $30 million financing round. According to a news release, proceeds from the financing will be used to fund a phase 2 combination trial of Ophthotechs E10030, the companys lead product candidate...
|
|
|
Roche posts 8% increase in sales for 2009
Submit a Comment BASEL, Switzerland Roche reported total sales of 49.05 billion Swiss francs for the full-year 2009, representing an 8% rise compared with sales reported during 2008, the company announced in a press release.Despite fourth-quarter reductions...
|
|
|
Kaiser study results on ranibizumab and bevacizumab
Ranibizumab was specifically developed to treat the wet form of AMD and received US Food and Drug Administration approval in 2006; bevacizumab was originally approved by the FDA as a cancer treatment and was used "off label" by ophthalmologists before ...
|
|
|
Strong operating performance for Roche in 2009
The total Roche Group's sales grew by 10% in local currencies (8% in Swiss francs; 7% in US dollars) to 49.1 billion Swiss francs, with the Pharmaceuticals Division accounting for 80% of Group sales and the Diagnostics Division contributing 20%.Sales growth...
|
|
|
Endothelial cells analysis after intravitreal ranibizumab (Lucentis) in age-related macular degeneration treatment: a pilot study
1Department of Ophthalmology, University Hospital Principe de Asturias, University of Alcal, Alcal de Henares, Madrid, Spain 2Department of Physiology, School of Medicine, University of Alcal, Alcal de Henares, Madrid, Spain Correspondence to Professor Consuelo...
|
|
|
Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand?
Choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) is responsible for 75% of the severe vision loss attributable to AMD.1 The pathogenesis of CNV is complex, involving angiogenic and vascular components.2 3 The current...
|
|
|
XOMA Announces Presentation at BIO CEO and Investor Conference on February 9
(GlobeNewswire via COMTEX News Network) -- XOMA Ltd.(Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that Steven B. Engle, Chairman and Chief Executive Officer of XOMA, is scheduled to present at the 12th annual...
|
|
|
XOMA Announces Presentation at BIO CEO and Investor Conference on February 9
BERKELEY, Calif., Feb 3, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd.(Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that Steven B. Engle, Chairman and Chief Executive Officer of XOMA, is scheduled...
|
|
|
XOMA Announces Presentation at BIO CEO and Investor Conference on February 9
BERKELEY, Calif., Feb.3, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced that Steven B. Engle, Chairman and Chief Executive Officer of XOMA, is scheduled to present at the 12th annual BIO...
|
|
|
XOMA Announces Presentation at BIO CEO and Investor Conference on February 9
BERKELEY, Calif., Feb.3, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced that Steven B. Engle, Chairman and Chief Executive Officer of XOMA, is scheduled to present at the 12th annual BIO...
|
|
|
BRAVO Study: Ranibizumab shows benefit in BRVO
New YorkAnalyses of data collected through 6 months in a phase III clinical trial show a strong benefit of intravitreal ranibizumab (Lucentis, Genentech) for clearing macular edema (ME) and rehabilitating vision in patients who have suffered a branch...
|
|
|
XOMA Announces Presentation at BIO CEO and Investor Conference on...
Company: XOMA Ltd.(XOMA) XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that Steven B. Engle, Chairman and Chief Executive Officer of XOMA, is scheduled to present at the 12th annual BIO CEO and...
|
|
|
XOMA Announces Presentation at BIO CEO and Investor Conference on February 9
BERKELEY, Calif., Feb.3, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that Steven B. Engle, Chairman and Chief Executive Officer of XOMA, is scheduled to present at the 12...
|
|
|
XOMA Announces Presentation at BIO CEO and Investor Conference on
BERKELEY, Calif., Feb.3, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that Steven B. Engle, Chairman and Chief Executive Officer of XOMA, is scheduled to present at the...
|
|
|
XOMA Announces Presentation at BIO CEO and Investor Conference on February 9
BERKELEY, Calif., Feb.3, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced that Steven B. Engle, Chairman and Chief Executive Officer of XOMA, is scheduled to present at the 12th annual BIO...
|
|
|
XOMA Announces Presentation at BIO CEO and Investor Conference on February 9
BERKELEY, Calif., Feb.3, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq The presentation will be webcast live at http://ceo.bio.org About XOMA XOMA discovers, develops and manufactures novel antibody therapeutics for its own proprietary pipeline as well as...
|
|
|
Swiss Roche posts CHF 8.5bn net profit for 2009
- Swiss drug producer Roche (VTX:ROG) reported on Wednesday a net profit of CHF 8.51 billion (USD 8.07bn/EUR 5.77bn) for 2009, a decrease of 22% compared with 2008.According to the company the drop is related to the integration of Genentech (NYSE:DNA), a US...
|
|
|
Strong operating performance for Roche in 2009
BASEL, Switzerland, Feb.3, 2010--Record sales, double-digit growth in operating profit and Core Earnings per share Dividend increase by 20% to 6.00 Swiss francs proposed Group Group sales increase by 10% to 49.1 billion Swiss francs (8% in Swiss francs, 7%...
|
|
|
Strong operating performance for Roche in 2009
BASEL, Switzerland, Feb.3, 2010--Record sales, double-digit growth in operating profit and Core Earnings per share Dividend increase by 20% to 6.00 Swiss francs proposed 1 LC= local currencies 2 Proposed by the Board of Directors. 3 before exceptional...
|
|
|
Roche profit climbs 4%; flu-meds sales rise
Roche Holding on Wednesday reported a 4% rise in second-half profit, buoyed by sales of flu medication Tamiflu and eye-disease drug Lucentis as sales growth slowed toward the end of the year.Though the company didn't provide second-half results,...
|
|
|
Genentech integration hits Roche profits
Roche achieved healthy sales growth in 2009 but saw a 22% drop in net income due to the cost gaining full control of Genentech and the companys subsequent restructuring.Net income fell to CHF 8.5 billion, but total sales were up 8% to CHF 49 billion, led by...
|
|
|
Roche profit climbs 4%; flu-meds sales rise
By Steve Goldstein, MarketWatch LONDON (MarketWatch) -- Roche Holding on Wednesday reported a 4% rise in second-half profit, buoyed by sales of flu medication Tamiflu and eye-disease drug Lucentis as sales growth slowed toward the end of the year.
|
|
|
Roche profit climbs 4%; flu-meds sales rise
LONDON (MarketWatch) -- Roche Holding on Wednesday reported a 4% rise in second-half profit, buoyed by sales of flu medication Tamiflu and eye-disease drug Lucentis as sales growth slowed toward the end of the year.Though the company didn't provide...
|
